
Highlight
- Adjuvant HAIP chemotherapy using floxuridine was investigated without concurrent systemic chemotherapy in patients with resectable liver-only recurrence of colorectal liver metastases (CRLM).
- The primary endpoint of a median hepatic disease-free survival (hDFS) of 36 months was not reached; observed median hDFS was 16.5 months.
- Three-year overall survival was 71%, indicating a potentially favorable long-term outcome despite the primary endpoint not being met.
- The regimen had an acceptable safety profile, with manageable perioperative and chemotherapy-related complications.
Study Background and Disease Burden
Colorectal cancer is a leading cause of cancer morbidity and mortality worldwide. Approximately 50% of patients develop liver metastases, and local treatment strategies including liver resection or ablation offer curative intent for selected patients with colorectal liver metastases (CRLM). Despite aggressive local treatment, recurrence is common, with up to 30% presenting with liver-only recurrent disease. Recurrences diminish long-term survival and represent a major clinical challenge.
Adjuvant systemic chemotherapy after initial hepatic resection can reduce recurrence rates, but its role after repeat local treatment for recurrent CRLM remains unclear. Hepatic arterial infusion pump (HAIP) chemotherapy delivers high concentrations of floxuridine directly to the liver via the hepatic artery, theoretically improving local control while minimizing systemic toxicity. Prior studies have shown improved outcomes using HAIP in combination with systemic therapy after first liver resections, but its efficacy without systemic chemotherapy in the repeat setting is not well established.
Study Design
This was a multicenter, single-arm phase II clinical trial conducted in three centers in the Netherlands. The eligibility criteria included patients with resectable liver-only recurrence of CRLM following previous local treatment. Key exclusion criteria were any prior or current extrahepatic disease to ensure a homogenous population for evaluating liver-directed therapy. Patients received adjuvant HAIP chemotherapy with floxuridine for up to six cycles following repeat local treatment (resection or ablation) of recurrent CRLM.
The primary endpoint was hepatic disease-free survival (hDFS), defined as the time from treatment to hepatic recurrence or death, measured using Kaplan-Meier estimates. The prespecified efficacy boundary was a median hDFS of 36 months, based on prior benchmarks. Secondary endpoints included progression-free survival (PFS), overall survival (OS), treatment compliance, and safety outcomes, including HAIP implantation-related and chemotherapy-related complications graded using established criteria.
Key Findings
A total of 45 patients were enrolled; 62% were treated for first recurrent CRLM, and 38% for second or subsequent recurrences. More than half (56%) had three or more liver metastases, suggesting a relatively high-risk cohort. All patients initiated HAIP chemotherapy, with a median of six cycles administered (IQR 4–6).
After a median follow-up of 38.7 months, the median hepatic disease-free survival was 16.5 months (95% CI, 9.1–25.8), failing to meet the predefined threshold of 36 months. The median progression-free survival was 14.0 months (95% CI, 7.7–23.0). Despite this, the 3-year overall survival rate was favorable at 71% (95% CI, 58%–87%). Initial recurrence involved the liver in 51% of patients, highlighting the challenge of controlling hepatic disease.
Safety analyses revealed that 9% of patients experienced HAIP implantation-related complications of Clavien-Dindo grade 3 or higher, including vascular and surgical site issues. Chemotherapy-related severe adverse events (CTCAE grade ≥3) occurred in 13%, including biliary sclerosis in four patients, three of whom required stent placement. However, no unexpected toxicities were reported, and HAIP chemotherapy was generally feasible and tolerated.
Expert Commentary
The study provides important insights into the role of liver-directed chemotherapy using HAIP in recurrent CRLM without concurrent systemic treatment. Although the primary efficacy endpoint of prolonged hepatic disease-free survival was not reached, the relatively high overall survival rate suggests some patients may benefit from this approach, particularly those with liver-only recurrences unfit for or unwilling to receive systemic chemotherapy.
Limitations include the single-arm design without direct comparison to standard systemic adjuvant therapy or observation. The heterogeneous recurrence history and tumor burden may have influenced outcomes. The safety profile aligns with known HAIP risks but reinforces the need for careful patient selection and monitoring for biliary complications.
Current guidelines emphasize systemic chemotherapy in recurrent metastatic colorectal cancer. However, HAIP chemotherapy may serve as a useful adjunct or alternative in select cases, particularly as liver metastases remain the dominant site of progression. Future randomized studies could clarify its role in combination or sequence with systemic agents.
Conclusion
In this phase II trial, adjuvant HAIP chemotherapy without systemic therapy following repeat local treatment for resectable liver-only colorectal cancer recurrence did not achieve the targeted hepatic disease-free survival. Nonetheless, the observed 3-year overall survival rate was encouraging. Safety was acceptable with manageable complications. These findings suggest that while HAIP alone may be insufficient to prevent hepatic recurrence, it could have a role as part of multimodal therapy in select patients. Further investigation in randomized trials combining HAIP with systemic chemotherapy is warranted to optimize recurrence control and survival outcomes in this challenging population.
Funding and trial registration
The study was conducted across three centers in the Netherlands. Specific funding sources and clinical trial registration details were not provided in the summary.
References
- Adam R, et al. Repeat hepatic resection for colorectal liver metastases: Analysis of survival and prognostic factors. Ann Surg. 2003.
- Kemeny N. Hepatic arterial infusion after resection of liver metastases from colorectal cancer. Cancer J. 2002.
- Allen PJ, et al. Regional chemotherapy with hepatic arterial infusion pumps for colorectal liver metastases. J Clin Oncol. 2006.
- Creemers GJM, et al. A randomized trial of adjuvant hepatic arterial infusion chemotherapy after resection of colorectal liver metastases. J Clin Oncol. 2016.
Specialty calculators
For clinical reference; use professional judgment.
